Live symbol workspace

ABBV market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $208.84

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$198.40

Resistance

$219.28

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$208.84

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

▼ 2.1 pts vs previous week

Avg confidence across 26 calls in the last 7 days

What sources say

Bullish 1 article

AbbVie (ABBV) Wins Health Canada Approval for Boey

Insider Trading

Insider	Role	Date	Type	Value
ROBERT J ALPERN	Director	May 26 '26	Proposed Sale	2781991.0
Purdue David Ryan	SVP, Controller	Mar 04 '26	Sale	1221519.0
David R. Purdue	Officer	Mar 04 '26	Proposed Sale	1221519.0
Siatis Perry C	EVP, GC …	Mar 02 '26	Sale	4375549.0
PERRY C SIATIS	Officer	Mar 02 '26	Proposed Sale	4375585.0
Siatis Perry C	EVP, GC …	Feb 25 '26	Option Exercise	3863458.0
Siatis Perry C	EVP, GC …	Feb 25 '26	Sale	5147630.0
PERRY C SIATIS	Officer	Feb 25 '26	Proposed Sale	5147630.0
Richard A. Gonzalez	Former Director	Aug 22 '25	Proposed Sale	13231264.0
Richard A. Gonzalez	Former Director	Aug 21 '25	Proposed Sale	18993948.0

Source: FinViz — Data may be delayed

Technical Observations

Refreshing technical observations from FinViz...

ABBV News Intelligence (8 articles)

AI-curated news influencing ABBV price, sentiment, and trend

Explore All ABBV News with AI Analysis

Stocks

3 months ago

Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.

Soleno Therapeutics stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy …

Impact on ABBV: Soleno Therapeutics' stock is soaring in premarket trading, with potential for a …

Neurocrine's potential acquisition of Soleno Therapeutics is driving a surge in Soleno's stock price, with … High (80%)

View full analysis →

MarketWatch 80% confidence

Economy

3 months, 2 weeks ago

Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

Impact on ABBV: AbbVie's (ABBV) undervaluation could lead to a price increase, potentially driving the …

AbbVie's strong financials, attractive dividend, and modest valuation make its stock appear undervalued, presenting a … High (70%)

View full analysis →

Yahoo Finance 70% confidence